周晓阳
中国医学科学院阜外医院 统计中心
BACKGROUND:The appropriate target for systolic blood pressure to reduce cardiovascular risk in older patients with hypertension remains unclear.METHODS:In this multicenter, randomized, controlled trial, we assigned Chinese patients 60 to 80 years of age with hypertension to a systolic blood-pressure target of 110 to less than 130 mm Hg (intensive treatment) or a target of 130 to less than 150 mm Hg (standard treatment). The primary outcome was a composite of stroke, acute coronary syndrome (acute myocardial infarction and hospitalization for unstable angina), acute decompensated heart failure, coronary revascularization, atrial fibrillation, or death from cardiovascular causes.RESULTS:Of the 9624 patients screened for eligibility, 8511 were enrolled in the trial; 4243 were randomly assigned to the intensive-treatment group and 4268 to the standard-treatment group. At 1 year of follow-up, the mean systolic blood pressure was 127.5 mm Hg in the intensive-treatment group and 135.3 mm Hg in the standard-treatment group. During a median follow-up period of 3.34 years, primary-outcome events occurred in 147 patients (3.5%) in the intensive-treatment group, as compared with 196 patients (4.6%) in the standard-treatment group (hazard ratio, 0.74; 95% confidence interval [CI], 0.60 to 0.92; P = 0.007). The results for most of the individual components of the primary outcome also favored intensive treatment: the hazard ratio for stroke was 0.67 (95% CI, 0.47 to 0.97), acute coronary syndrome 0.67 (95% CI, 0.47 to 0.94), acute decompensated heart failure 0.27 (95% CI, 0.08 to 0.98), coronary revascularization 0.69 (95% CI, 0.40 to 1.18), atrial fibrillation 0.96 (95% CI, 0.55 to 1.68), and death from cardiovascular causes 0.72 (95% CI, 0.39 to 1.32). The results for safety and renal outcomes did not differ significantly between the two groups, except for the incidence of hypotension, which was higher in the intensive-treatment group.CONCLUSIONS:In older patients with hypertension, intensive treatment with a systolic blood-pressure target of 110 to less than 130 mm Hg resulted in a lower incidence of cardiovascular events than standard treatment with a target of 130 to less than 150 mm Hg. (Funded by the Chinese Academy of Medical Sciences and others; STEP ClinicalTrials.gov number, NCT03015311.).
The New England journal of medicine 2021
We performed a meta-analysis of 2 genome-wide association studies of coronary artery disease comprising 1,515 cases and 5,019 controls followed by replication studies in 15,460 cases and 11,472 controls, all of Chinese Han ancestry. We identify four new loci for coronary artery disease that reached the threshold of genome-wide significance (P < 5 × 10(-8)). These loci mapped in or near TTC32-WDR35, GUCY1A3, C6orf10-BTNL2 and ATP2B1. We also replicated four loci previously identified in European populations (in or near PHACTR1, TCF21, CDKN2A-CDKN2B and C12orf51). These findings provide new insights into pathways contributing to the susceptibility for coronary artery disease in the Chinese Han population.
Nature genetics 2012
BACKGROUND:Although the role of fibrinogen as a predictor of acute myocardial infarction (MI) has been well-established, the association of genetic polymorphisms in the fibrinogen gene with MI is still controversial. This study was conducted to elucidate the association between the genetic polymorphisms of the fibrinogen beta-chain (FGB) gene and MI in Chinese Han population.METHODS:The occurrence of 3 common polymorphisms (i.e., -455G/A, R448K and 8558C/G) in a case-control study including 508 patients with MI and 503 healthy controls was investigated. Results Analyses of single polymorphisms showed that individuals carrying the rare alleles for the 3 polymorphisms were significantly associated with a decreased risk of MI. Logistic regression analysis indicated that R448K remained independently associated with MI after adjustment for environmental risk factors (adjusted odds ratio(OR) = 0.71 for KK/RK versus RR, P = 0.023). The three polymorphisms were found to be in strong linkage disequilibrium. Haplotype analyses showed that the A-K-G haplotype (-455A, 448K, 8558G) was associated with a protective effect against MI. Compared with the common haplotype G-R-C, the adjusted OR for A-K-G was 0.68 (95% CI, 0.51-0.90; P = 0.006).CONCLUSION:These data indicate that individuals carrying the FGB 448K allele may be protective against having MI in this population.
Chinese medical journal 2008
Matrix metalloproteinase (MMP) 3 plays an important role in the pathogenesis of myocardial infarction (MI). Up to now, there has been conflicting data regarding the possible contribution of the MMP3 -1612 5A/6A promoter polymorphism to MI. In this study, we have investigated the possible association of three polymorphisms (-1612 5A/6A, -376C/G, Glu45Lys) in the MMP3 gene with MI in a Chinese Han population. The polymorphisms were analyzed in 509 patients with MI, and in 518 healthy controls. The frequency of the 5A allele was 14% in the healthy controls, which is less than in Western populations (40%-52%). Logistic regression analyses of individual polymorphisms indicated that individuals carrying the -1612 5A allele had an increased risk of MI (odds ratio [OR] 1.75, 95% confidence interval [CI] 1.28 to 2.40), as did those carrying the -376 G allele (OR 1.78, 95% CI 1.33 to 2.38). The three polymorphisms studied were found to be in strong linkage disequilibria. Haplotype analyses showed that the 5A-G-Lys haplotype (-1612 5A, -376G and 45Lys) was independently associated with susceptibility to MI. Taken together, the effect of the MMP3 polymorphisms studied may be attributable to the -1612 5A/6A polymorphism. We conclude that the MMP3 -1612 5A/6A polymorphism is associated with MI in our population, implying that individuals of the 5A allele carriers have an increased risk of suffering MI.
Thrombosis and haemostasis 2004
INTRODUCTION:Thrombospondin-1 (TSP-1) is very important in platelet adhesion and aggregation, inflammation, cell to cell interaction, and vascular smooth muscle cell proliferation. Therefore, it may play an important role in the progression of cardiovascular disease. Recently, the TSP-1 N700S variant was proposed to be a new genetic predictor for myocardial infarction (MI) in American population, but the hypothesis was not verified in two other populations. We investigated a possible association between the N700S polymorphism and MI in a Chinese Han population.MATERIALS AND METHODS:We performed a case-control study including 406 patients who survived an acute MI before age 60 years and 400 age- and sex-matched controls. The N700S polymorphism was determined by polymerase chain reaction and restriction fragment length polymorphism.RESULTS:Of the 806 subjects participating in the study, only 7 of the heterozygotes and none of the homozygotes were detected for the 700S allele. The prevalence of the S allele in the healthy controls was less frequent than those of the west populations (0.3% vs. 11%). No association of the N700S polymorphism with an altered risk of MI was found in our study (GA vs. AA: OR=2.48; 95% CI, 0.48 to 12.86; P=0.46).CONCLUSIONS:Our study suggested that the TSP-1 N700S polymorphism was rare and unrelated to MI in the Chinese Han population. Additional investigations should be performed in populations at different risk for coronary events in order to further elucidate the possible contribution of the polymorphism to cardiovascular disease.
Thrombosis research 2004
Recently, conflicting data have been reported regarding the possible contribution of the TSP-4 (thrombospondin-4) A387P polymorphism to CAD (coronary artery disease) or MI (myocardial infarction). To investigate a possible association between the A387P polymorphism and CAD or MI in the Chinese Han population, we conducted a case-controlled study including 817 patients with angiographically verified CAD or those who survived an acute MI and 847 control subjects. The TSP-4 A387P polymorphism was determined by PCR and PCR-RFLP (restriction-fragment-length polymorphism) analysis. The prevalence of the 387P allele was 3.8% in the healthy controls, which was less frequent than those in Western populations (19.6-23.2%). No association of the A387P polymorphism with an altered risk of CAD, MI or premature MI was found in our present study (CG+CC compared with GG, P (CAD)=0.51, P (MI)=0.13, P (Premature MI)=0.17 respectively). We concluded that a relationship between the TSP-4 A387P polymorphism and CAD or MI was unlikely in our population. Additional investigations should be performed in populations at different risk of coronary events in order to elucidate further the possible contribution of this polymorphism to cardiovascular disease.
Clinical science (London, England : 1979) 2004